Zepbound sales keep soaring, even as weight loss drug growth slows
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s initial sales expectations.
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast lower-than-expected fourth-quarter revenues for the drug.
How Weight-Loss Drugs Can Upend a Marriage
When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of conversations with her husband, Javier. They were in
LLY Earnings: Weight Loss Drug Demand Drives Eli Lilly Sales as Investors Eye Next-Gen Treatments
Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in
Lilly forecasts 2025 profit largely above estimates on weight-loss drug strength
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular diabetes and weight-loss treatments in new markets. The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug Zepbound for the second straight quarter.
Eli Lilly Earnings Top, 2025 Guidance Strong, But Weight-Loss Drug Sales Miss
Eli Lilly earnings topped Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.
Lilly's profit forecast bring investors some relief amid Zepbound miss
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...
BioSpace15h
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...
Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says
Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.
Lilly reassures investors that weight-loss drug demand is strong, shares rise
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
Eli Lilly and Co (LLY) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
Eli Lilly and Co (LLY) reports a 45% increase in Q4 revenue, driven by new products, while outlining ambitious growth and ...
Zacks.com on MSN16h
LLY's Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy of Estimates
Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...
Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Why did Eli Lilly report mixed Q4 results despite soaring demand for Zepbound and Mounjaro?
Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales ...